EMT Chapter 26-MCIT-F3-2216 | The Toxicology Takeover

EMT Chapter 26-MCIT-F3-2216 | The Toxicology Takeover:  This course is built for the modern EMT facing a drug landscape that no longer follows the old rules. Today’s overdoses are rarely simple, often layered, and frequently deceptive-requiring structured thinking under pressure than reflex treatment. 

The lessons covered are

  • Lesson 1:  The New Drug Landscape
  • Lesson 2:  The Alpha-2 Invasion
  • Lesson 3:  The Chameleon Drugs
  • Lesson 4:  The New Assessment Framework, and,
  • Lesson 5:  Putting It All to Work

Excerpt from EMT Chapter 26-MCIT-F3-2216 | The Toxicology Takeover

Morphine is at 1. Heroin turns it up to 2. Fentanyl cranks it to 100, which is why it became so dangerous so fast. But here is what a lot of providers do not realize yet: we have now moved past fentanyl as the ceiling. Nightazeenz, drugs like protonitazene and ee-toe-nyetahzeen, are 10 to 40 times more potent than fentanyl. Kar-FEN-tuh-nil, which was developed to sedate elephants, clocks in at roughly 10,000 times morphine.

Now, you might be thinking – that seems almost unreal. How do you even dose something like that? The answer is: you barely do, and that is exactly the problem. The margin between a dose that gets someone high and a dose that kills them is essentially invisible. Street users have no idea what they are getting, and neither do you when you arrive on scene.

The other critical concept here is binding affinity. These drugs do not just hit harder – they grip the receptor tighter than Naloxone does. That is why standard doses of Narcan fail on some of these calls. We will return to that idea repeatedly throughout this course, because it changes how you think about dosing and transport decisions.

 

 

Core Concepts & Takeaways

  • Describe the mechanism by which ultra-potent synthetic opioids (nightazeenz, kar-FEN-tuh-nil) reduce the effectiveness of Naloxone and identify the clinical indicators of Recoil apnea during patient transport.
  • Differentiate alpha-2 agonist sedation from opioid-only overdose presentations based on vital sign patterns, skin findings, and response to Naloxone administration.
  • Identify the concealed opioid risk in patients presenting with Too-see (Pink Cocaine) intoxication and apply appropriate monitoring and intervention strategies for the stimulant-to-opioid physiologic transition.
  • Evaluate a suspected Tye-uhnepteene overdose for dual-threat toxicity by recognizing both the opioid and TCA-like cardiac components and prioritizing field interventions accordingly. And,
  • Apply the five-step substance-aware assessment framework to modern overdose presentations to identify the dominant threat class, match interventions to physiology, and formulate a precise clinical handoff communication.

 

 

Important Notes:

To get credit for this course, you must watch all the lessons in their entirety, the course review, and pass the quiz at the end with a score of 75% or better.

Course Curriculum

EMT Chapter 26-MCIT-F3-2216 | The Toxicology Takeover

  • Lesson 0 – Introduction
    02:43
  • Lesson 1 – The New Drug Landscape: Why Everything You Learned about Overdose is Changing
    10:41
  • Lesson 2: The Alpha-2 Invasion: Xylazine, Medetomidine, and The Drug Naloxone Cannot Touch
    15:05
  • Lesson 3 – The Chameleon Drugs: Tusi, Pink Cocaine & Tianeptine: When the Patient Doesn’t Look Like an Overdose
    15:02
  • Lesson 4 – The New Assessment Framework: Putting It All Together – A Unified Field Approach for the Modern Overdose
    15:56
  • Lesson 5 – Putting it All to Work: Scenario-Based Application and Course Knowledge Check
    16:32
  • Lesson 6 – Chapter Review
    04:48
  • EMT Chapter 26-MCIT-F3-2216 | The Toxicology Takeover | QUIZ
Course Content / Training Video Feedback

You do not have permission to view this form.

An application for accreditation has been submitted to the Commission on Accreditation for Pre-Hospital Continuing Education.

Disclosure: The planners, faculty, and content developers of this activity have no relevant financial relationships or commercial interests to disclose. No commercial support was received for this activity.

$32.50
Course Duration: 1h 21m
Fill out the form below, and we will send you an email with the whitepaper.
Mandated Reporting Whitepaper
Name
Name
First
Last